Clinical bottom line
Direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection have demonstrated substantial benefits beyond viral clearance, notably improving or resolving many extrahepatic manifestations (EHMs). Evidence indicates that successful DAA therapy reduces the burden of HCV-associated conditions such as mixed cryoglobulinemia, dermatologic disorders, and certain neurologic complications. However, the impact on extrahepatic malignancies remains less clear. Early initiation of DAAs and comprehensive patient evaluation are key to optimizing outcomes in patients with EHMs (Balta et al., 2025; Salama et al., 2022).
What the evidence shows
Balta et al. (2025) provide a narrative review highlighting that DAAs effectively reduce HCV RNA, which correlates with improvement in EHMs including vasculitis, renal disease, and metabolic disturbances. Their hermeneutic approach underscores the multifactorial mechanisms by which viral eradication ameliorates systemic inflammation and immune dysregulation.
Salama et al. (2022) report on hepatic and extrahepatic outcomes post-DAA therapy, demonstrating significant remission rates of cutaneous manifestations and neurological symptoms. They note that while DAAs improve many EHMs, some neurologic disorders may persist or require adjunctive therapies.
Chemello et al. (2021) focus on neurologic disorders associated with chronic HCV, showing that DAAs reduce symptom severity in peripheral neuropathy and cognitive impairment, though recovery may be incomplete in advanced cases.
Mazzaro et al. (2021) review the broad spectrum of EHMs and confirm that DAA-induced sustained virologic response (SVR) is associated with decreased incidence and severity of systemic manifestations, including cryoglobulinemic vasculitis and renal involvement.
Kassas et al. (2020) provide evidence that DAAs improve extrahepatic cutaneous manifestations such as lichen planus and porphyria cutanea tarda, with clinical remission observed in a majority of treated patients.
Méndez-Sánchez et al. (2024) discuss the ongoing uncertainty regarding the impact of DAAs on extrahepatic cancers, noting conflicting data and the need for further long-term studies.
Caveats and uncertainty
Most data derive from observational studies and retrospective cohorts, limiting causal inference.
Heterogeneity in EHM definitions and assessment complicates comparisons.
Neurologic and some autoimmune manifestations may not fully resolve despite viral clearance.
The relationship between DAA therapy and risk modification for extrahepatic malignancies remains inconclusive.
Long-term follow-up data on EHM outcomes post-DAA are limited.
How this may change practice
Clinicians should recognize the broad systemic benefits of DAA therapy beyond liver disease, incorporating EHM assessment into routine HCV management.
Early antiviral treatment is advisable to prevent irreversible organ damage from EHMs.
Multidisciplinary collaboration with rheumatology, neurology, dermatology, and oncology specialists may optimize care for complex EHM presentations.
Ongoing monitoring for persistent or emerging EHMs post-SVR remains important.
Further research and registries are needed to clarify long-term EHM trajectories and cancer risk post-DAA.